Singapore

The Health Sciences Authority (HSA) is Singapore's primary regulatory body responsible for the registration and market authorisation of health products, including pharmaceuticals, medical devices, diagnostics, and digital health solutions. HSA operates under the Health Products Act (HPA) and its subsidiary legislation, which provide the legal framework for product registration, licensing, and post-market surveillance. Applicants must obtain product registration or listing approval before commercialisation, with submission routes tiered by risk level and the regulatory status of the product in reference jurisdictions. HSA employs a risk-based classification system, and the review pathway, whether full, abridged, or verification, depends on prior approvals from recognised reference agencies such as the US FDA, EMA, TGA, Health Canada, and others within the ASEAN network.

Key submission requirements include the appointment of a local Registrant or Product Licence Holder, who must be a Singapore-registered legal entity responsible for regulatory compliance and post-market obligations. Dossiers are generally accepted in Common Technical Document (CTD) or ASEAN Common Technical Dossier (ACTD) format, depending on the product category. For medical devices, submissions follow the ASEAN Medical Device Directive (AMDD) framework, and HSA actively participates in the Medical Device Single Audit Program (MDSAP) and the International Medical Device Regulators Forum (IMDRF). Notable recent reforms include the progressive expansion of the HSA Innovative Products (IP) pathway for breakthrough therapies, the regulatory sandbox framework for digital health and Software as a Medical Device (SaMD), and ongoing harmonisation efforts under the ASEAN regulatory convergence agenda to streamline multi-market approvals across the region.

Public sector procurement in Singapore is centralised and highly structured, overseen by the Ministry of Health (MOH) and executed primarily through the Ministry of Health Holdings (MOHH), which manages the public healthcare clusters: National University Health System (NUHS), National Healthcare Group (NHG), and Singapore Health Services (SingHealth). Tenders for pharmaceuticals, medical devices, and diagnostics are coordinated through these clusters, often via centralised bulk contracting mechanisms that leverage collective purchasing power across public hospitals, polyclinics, and specialist centres. The Government Procurement Act and associated regulations govern tendering procedures, with public tenders published on the GeBIZ (Government Electronic Business) portal. National formulary listing via the Standard Drug List (SDL) and the Standard Medical Supply List is a prerequisite for reimbursement in the public sector, and companies must engage with MOH's pharmaceutical and supply chain offices to initiate formulary inclusion discussions.

Singapore's private healthcare sector is substantial and operates through a parallel, commercially driven procurement channel involving private hospital groups such as Raffles Medical Group, Parkway Pantai, and Thomson Medical. Procurement in this sector is negotiated directly between suppliers and hospital procurement teams or group purchasing organisations, with pricing subject to competitive market dynamics. Singapore is a high-income country and is generally not a recipient of donor-funded health procurement through mechanisms such as UNICEF Supply Division, the Global Fund, USAID, or Gavi; however, Singapore-based entities and regional hubs, including those affiliated with UNICEF and WHO, play a role in coordinating supply chain support for the broader Asia-Pacific region. There are no formal local manufacturing preference policies mandated by law, though MOH may consider supply chain resilience and local production capacity, particularly for essential medicines and pandemic-critical products, as part of strategic stockpiling and national health security initiatives.